Kelly G. Paulson, MD, PhD, on Extensive-Stage SCLC: Tarlatamab Plus Anti–PD-L1 as Maintenance Therapy

September 15, 2025 By The ASCO Post Staff

Kelly G. Paulson, MD, PhD, of Providence Swedish Cancer Institute (Seattle, WA) and lead of the Center for Immuno-Oncology at Paul G. Allen Research Center, reviews findings from the safety and efficacy data from the phase Ib DeLLphi-303 trial. The study examined tarlatamab, a bispecific T-cell engager, in combination with PD-L1 inhibition as first-line maintenance; the regimen led to unprecedented overall survival results in this patient population, and had an acceptable safety profile (Abstract OA13.01). 

For more information on DeLLphi-303, read more in The Lancet Oncology.

 

Related Content